Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...

Speaking on the development, Chairman of Zydus Lifesciences Limited, Pankaj Patel, said, “This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

HB-adMSCs is under clinical development by Hope Biosciences and currently in Phase I for Primary Lateral Sclerosis. According to GlobalData, Phase I drugs for Primary Lateral Sclerosis does not have ...

Its pipeline products include PIPE-791, an LPA1 receptor antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective inhibitor of the M1 receptor ...

a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS). Usnoflast (ZYIL1) is a novel, oral small molecule NLRP3 inhibitor. Usnoflast has been studied in several ...

a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS). Under the leadership of Principal Investigator Prof Merit Cudkowicz, MD, Director of the Sean M. Healey ...

During his departure announcement in 2024, Neil thanked his bosses for their patience when he took off “a day or two here and there battling everything from multiple sclerosis and COVID to ...

Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...